Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)
Journal of Cancer Research and Clinical Oncology · 01.10.2024 · 150 (10)
DOI: 10.1007/s00432-024-05954-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 01.10.2024. Verfasst von David Witte und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Palliative Care, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. david.witte@ruhr-uni-bochum.de. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Pyridones, Antineoplastic Combined Chemotherapy Protocols, Pyrimidinones. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Katholisches Klinikum Bochum gGmbh.
Abstract (Originalsprache)
Background
Preclinical models of pancreatic cancer (PDAC) suggest a synergistic role for combined MEK and autophagy signaling inhibition, as well as MEK and CDK4/6 pathway targeting. Several case reports implicate clinical activity of the combination of either trametinib and hydroxychloroquine (HCQ) in patients with KRAS-mutant PDAC or trametinib with CDK4/6 inhibitors in patients with KRAS and CDKN2A/B alterations. However, prospective data from clinical trials is lacking. Here, we aim to provide clinical evidence regarding the use of these experimental regimens in the setting of dedicated precision oncology programs.
Methods
In this retrospective case series, PDAC patients who received either trametinib/HCQ (THCQ) or trametinib/palbociclib (TP) were retrospectively identified across 11 participating cancer centers in Germany.
Results
Overall, 34 patients were identified. 19 patients received THCQ, and 15 received TP, respectively. In patients treated with THCQ, the median duration of treatment was 46 days, median progression-free survival (PFS) was 52 days and median overall survival (OS) was 68 days. In the THCQ subgroup, all patients evaluable for response (13/19) had progressive disease (PD) within 100 days. In the TP subgroup, the median duration of treatment was 60 days, median PFS was 56 days and median OS was 195 days. In the TP subgroup, 9/15 patients were evaluable for response, of which 1/9 showed a partial response (PR) while 8/9 had PD. One patient achieved a clinical benefit despite progression under TP.
Conclusion
THCQ and TP are not effective in patients with advanced PDAC harboring KRAS mutations or alterations in MAPK/CDKN2A/B.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Palliative Care, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. david.witte@ruhr-uni-bochum.de.
- West German Cancer Center, University Hospital Essen, Essen, Germany.
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Hematology-Oncology Practice Eppendorf, University Cancer Center Hamburg, Hamburg, Germany.
- Department of Oncology, Hematology and BMT with Section Pneumology, University of Hamburg, Hamburg, Germany.
Förderung
- Katholisches Klinikum Bochum gGmbh
Zitieren
APA
Witte, D., Pretzell, I., Reissig, T. M., Stein, A., Velthaus, J. L., Alig, A., Bohnenberger, H., Knödler, M., Kurreck, A., Sulzer, S., Beyer, G., Dorman, K., Fröhlich, T., Hegenberg, S., Lugnier, C., Saborowski, A., Vogel, A., Lange, S., Reichert, M., …, & Westphalen, C. B. (2024). Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123). Journal of Cancer Research and Clinical Oncology, 150(10). https://doi.org/10.1007/s00432-024-05954-5
Vancouver
Witte D, Pretzell I, Reissig TM, Stein A, Velthaus JL, Alig A, et al. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123). Journal of Cancer Research and Clinical Oncology. 2024;150(10). doi:10.1007/s00432-024-05954-5
BibTeX
@article{Witte2024,
author = {Witte, David and Pretzell, Ina and Reissig, Timm M and Stein, Alexander and Velthaus, Janna-Lisa and Alig, Annabel and Bohnenberger, Hanibal and Knödler, Maren and Kurreck, Annika and Sulzer, Sabrina and Beyer, Georg and Dorman, Klara and Fröhlich, Tabea and Hegenberg, Stefanie and Lugnier, Celine and Saborowski, Anna and Vogel, Arndt and Lange, Sebastian and Reichert, Maximilian and Flade, Franziska and Klaas, Lioba and Utpatel, Kirsten and Becker, Heiko and Bleckmann, Annalen and Wethmar, Klaus and Reinacher-Schick, Anke and Westphalen, Christoph Benedikt},
title = {Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
volume = {150},
number = {10},
doi = {10.1007/s00432-024-05954-5}
}
EUVIMED